Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BRIEF-Repros Therapeutics says EU submission of Enclomiphene on track

By: Reuters: Company News
* Repros provides update on EU submission of enclomiphene for the treatment of secondary hypogonadism and 3 month interim results for enclomiphene study in obese secondary hypogonadal men
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.